Range Financial Group LLC Purchases New Stake in Organon & Co. (NYSE:OGN)

Range Financial Group LLC purchased a new position in shares of Organon & Co. (NYSE:OGN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 55,435 shares of the company's stock, valued at approximately $827,000.

A number of other institutional investors have also modified their holdings of OGN. LSV Asset Management lifted its holdings in Organon & Co. by 47.3% in the second quarter. LSV Asset Management now owns 6,610,768 shares of the company's stock valued at $136,843,000 after acquiring an additional 2,121,940 shares during the period. Geode Capital Management LLC lifted its stake in shares of Organon & Co. by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company's stock valued at $81,288,000 after purchasing an additional 82,220 shares during the period. AQR Capital Management LLC boosted its holdings in Organon & Co. by 39.8% during the second quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company's stock worth $71,905,000 after buying an additional 988,336 shares in the last quarter. Deprince Race & Zollo Inc. grew its position in Organon & Co. by 6.8% during the second quarter. Deprince Race & Zollo Inc. now owns 3,421,703 shares of the company's stock valued at $70,829,000 after buying an additional 216,907 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Organon & Co. by 35.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company's stock valued at $63,570,000 after buying an additional 875,128 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Price Performance

Organon & Co. stock traded up $0.26 during trading on Tuesday, reaching $15.74. The company had a trading volume of 2,641,994 shares, compared to its average volume of 2,840,398. The firm has a market capitalization of $4.05 billion, a PE ratio of 3.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.76. The firm's 50-day simple moving average is $15.50 and its 200 day simple moving average is $18.47. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same quarter last year, the business earned $0.78 EPS. The firm's revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were given a $0.28 dividend. The ex-dividend date was Tuesday, November 12th. This represents a $1.12 annualized dividend and a dividend yield of 7.12%. Organon & Co.'s dividend payout ratio (DPR) is presently 22.22%.

Analyst Ratings Changes

Separately, Evercore ISI raised shares of Organon & Co. to a "strong-buy" rating in a research note on Wednesday, September 18th.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.